Summary
The protein coded by the oncogene c-myc, p62c-myc, was measured using monoclonal antibodies and flow cytometry in nuclei derived from paraffin-wax sections of transitional cell carcinomas of the human bladder. Superficial disease (stages pTa and pT1) which did not recur within 5 years of diagnosis had significantly higher oncoprotein levels than those which did recur or were muscle-invasive (stage pT2 or greater) at presentation (P<0.01). These preliminary findings indicate that oncoprotein levels might have prognostic significance for bladder cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bishop JM (1987) The molecular genetics of cancer. Science 235:305–311
Evan GI, Hancock DC (1985) Studies on the interaction of the human c-myc protein with cell nuclei: p62c-myc as a member of a discrete subset of nuclear proteins. Cell 43:253–261
Evan G, Lewis GK, Ramsay G, Bishop JM (1985) Isolation of monoclonal antibodies specific for human and mouse protooncogene products. Mol Cell Biol 5:3610–3616
Forgacs IC, Sunderesan V, Evan G, Wight DGD, Neale G, Hunter JO, Watson JV (1986) Abnormal expression of c-myc oncogene product in dysplasia and neoplasia associated with ulcerative colitis. Gut 27:A1285
Hedley DW, Friedlander MI, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333–1335
Hendy-Ibbs P, Cox H, Evan GI, Watson JV (1987) Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia. Br J Cancer 55:215–282
Kelly K, Cochran BH, Stiles CD, Leder P (1984) The regulation of c-myc by growth signals. Curr Top Microbiol Immunol 113:117–126
Lum BL (1983) Intravesical chemotherapy of superficial bladder cancer. Recent Results Cancer Res 85:3–36
Rabbitts PH, Watson JV, Lamond A, Fischer W, Forester A, Stinton MA, Evan GI, Atherton E, Sheppard RC, Rabbitts TH (1985) Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J 4:2009–2015
Sikora K, Evan G, Stewart J, Watson JV (1985) Detection of the c-myc oncogene product in testicular cancer. Br J Cancer 52:171–176
Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, Watson JV (1987) c-myc oncogene expression in colorectal cancer. Cancer 59:1289–1295
Stewart J, Evan GI, Watson JV, Sikora KE (1986) Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer 53:1–6
Studzinski GP, Brulei ZS, Feldman SC, Watt RA (1986) Participation of c-myc protein in DNA synthesis of human cells. Science 234:467–470
Watson JV (1980) Enzyme kinetic studies in cell populations using fluorogenic substrates and flow cytometric techniques. Cytometry 1:143–151
Watson JV (1985) A method for improving light collection by 600% from square cross section flow cytometry chambers. Br J Cancer 51:433–435
Watson JV (1986) Oncogenes, cancer and analytical cytology. Cytometry 7:400–410
Watson JV, Sikora KE, Evan GI (1985) A simultaneous flow cytometric assay for c-myc oncoprotein and cellular DNA in nuclei from paraffin embedded material. J Immunol Methods 83:179–192
Watson JV, Stewart J, Ritson A, Evan GI, Sikora EK (1986) The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer 53:331–337
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Masters, J.R.W., Vesey, S.G., Munn, C.F. et al. c-myc oncoprotein levels in bladder cancer. Urol. Res. 16, 341–344 (1988). https://doi.org/10.1007/BF00256039
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256039